Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

AP News

Nevada gets $1.5M in diabetes drug settlement

LAS VEGAS (AP) — Nevada is getting $1.5 million to settle claims that GlaxoSmithKline deceptively promoted the diabetes drug Avandia.

Nevada Attorney General Catherine Cortez Masto says Thursday that Nevada's portion is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.

The attorneys general claim the company misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices, and to publicize information about any company-sponsored clinical trials on its diabetes drugs.

A GlaxoSmithKline spokeswoman says the settlement doesn't admit any wrongdoing. She says the company firmly believes it acted responsibly in testing, marketing, and monitoring the safety of Avandia.

blog comments powered by Disqus